Heartseed Company Description

Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure.

The company’s lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy.

It also develops products using autologous iPSC and HLA knock-out iPSC. In addition, the company offers differentiation induction, mass culture, purification, and myocardial globule production technology.

The company was incorporated in 2015 and is headquartered in Tokyo, Japan.

Heartseed Inc.

Country	Japan
Founded	2015
Industry	Medical - Pharmaceuticals
Sector	Healthcare
CEO	Keiichi Fukuda

Contact Details

Address: Seavans South Building Tokyo, 105-0023 Japan
Phone	81 3 6665 8068
Website	heartseed.jp

Stock Details

Ticker Symbol	219A
Exchange	Tokyo Stock Exchange
Fiscal Year	November - October
Reporting Currency	JPY
ISIN Number	JP3765140003
SIC Code	2836

Key Executives

Name	Position
Keiichi Fukuda	Chief Executive Officer
Kikuo Yasui	Chief Operating Officer